New combo attack on Tough-to-Treat cancers

NCT ID NCT03210662

Summary

This study tested whether combining a type of immunotherapy (pembrolizumab) with targeted radiation could help patients whose aggressive non-Hodgkin lymphoma had come back or stopped responding to other treatments. The goal was to see if the combination could shrink tumors and control the disease better than immunotherapy alone. It involved 17 patients who received both treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT T-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.